John Orloff

Cantai seeks to develop drug candidates to treat autoimmune and inflammatory disorders by developing cytokine-targeting bispecific antibodies that meaningfully improve the status quo for the millions of patients suffering from immune-mediated and autoimmune diseases.

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and delivery of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbiopharma.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Venture Partner, Agent Capital Agent Capital is an international life sciences investment firm that supports disruptive healthcare companies focusing on novel, differentiated therapeutics and treatments that address unmet patient needs. Agent Capital aligns with scientists, entrepreneurs, and other investors to develop the next generation of healthcare innovations, leverages their industry expertise and successful track record to source premier deals, accelerate value, and drive successful exits. Their first fund invested in 15 portfolio companies, the majority of which have executed collaborations with major pharmaceutical companies and successfully raised additional capital in the private or public markets. For more information, please visit Agent Capital’s website at www.agentcapital.com.

GLG Institute is transforming the way the world’s top executives share expertise, learn, and accelerate their development. Senior executives learn fastest through conversation with other professionals who can share relevant experience and hard-won perspectives. GLG Institute is designed to create those conversations. We recruit the world’s best operators, leaders, and policy makers to serve as Advisors to GLG Institute Members.

Non-executive Director, Benevolent AI BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

Led a worldwide organization highly skilled in rare disease drug development with scientific expertise in complement biology. Dr. Orloff was instrumental in leading an overhaul of the R&D function, with recruitment of new talent and the re-organization of Clinical Development, Development Operations and Quantitative Sciences, Medical Affairs, Global Drug Safety, Product Development and Clinical Supply, and Program and Portfolio Management, and Discovery Research. The transformation of R&D focused internal research on complement, where Alexion is a recognized leader, and development work on both complement- and non-complement-mediated targets within seven franchises: hematology, nephrology, neurology, ophthalmology, cardiology, metabolic diseases, and acute care. Over a period of 3 years, Dr. Orloff led the expansion of the development pipeline from 3 to nearly 30 clinical-stage development programs across 12 assets, spanning over 80 clinical trials from Phase 1 to Phase 4, and expanding from 6 disease areas in 2017 to 23 in 2020. He also drove a significant increase in productivity from internal discovery research, with the delivery of 3 novel INDs, and the goal to deliver at least 5 new INDs by 2025. Dr. Orloff exited Alexion in July 2021 following the acquisition by AstraZeneca.

Executive Vice President, Global Head of R&D at Novelion. Therapies focused on rare metabolic disease.

Advanced Baxalta’s pipeline by employing an external innovation model (Hematology, Immunology, and Oncology). Lead ~1300 people spanning discovery research to LCM; Section 16 Officer, representing R&D at all Executive Committee meetings, Board interactions, investor/external community engagements. During a span of 2 years, oversaw regulatory approval of 10 unique products (Adynovate, Vonvendi, Cuvitru, Rixubis, HyQvia, Oncaspar, Onivyde, Flexbumin 5%, Obizur, FEIBA prophy) and 2 devices (BaxJet III, MyPKFiT) in major markets (US and EU). Baxalta was ranked 1st overall in the Patient View Corporate Reputation of Pharma among Rare Disease Patient Groups (2015 survey).

Responsible for advancing the BioScience pipeline, enhancing the current R&D operating model, and pursuing additional innovative opportunities for the business, as Baxter BioSciences works toward becoming an independent global biopharmaceutical company.

Led design / execution of global clinical development programs & projects, driving quality execution of the projects after proof-of-concept. Oversaw pipeline management / development, working collaboratively with research teams & commercial to drive efficient development of Merck's portfolio.

Chemistry major, graduated Phi Beta Kappa and Magna Cum Laude. Ski team.